Journal of human reproductive sciences · 2025
Gonadotropin-releasing Hormone Antagonist versus Fixed Progestin-Primed Ovarian Stimulation in In vitro Fertilisation: A Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kothekar Manjushri Amol, Jagtap Richa A, Katiyar Parul, Fatemi Human M, Lawrenz Barbara
Аннотация
BACKGROUND: Investigators have compared progestin-primed ovarian stimulation (PPOS) and conventional stimulations in multiple studies, however, with contrasting observations with respect to in vitro fertilisation (IVF) cycle outcomes. The extent of serum luteinising hormone (LH) suppression has not been studied much between the protocols.
AIM: The primary aim of this study was to compare IVF cycle outcomes in terms of oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation and cumulative pregnancy rate between gonadotropin-releasing hormone (GnRH) antagonist protocol and fixed PPOS protocol. The secondary aim was to compare the extent of pituitary suppression as reflected by serum LH before final oocyte maturation between both the protocols.
SETTINGS AND DESIGN: This was a retrospective observational cohort study.
MATERIALS AND METHODS: All ovarian stimulation cycles, either performed as GnRH-antagonist or as fixed PPOS, between 1st October 2023 and 15th July 2024, at a tertiary level IVF centre were included. Egg freezing cycles and donor egg cycles were excluded.
STATISTICAL ANALYSIS USED: Statistical tests applied were Student's t-test two-tailed for interval/ratio variables and the Chi-square test for nominal variables with a significance level of 0.05.
RESULTS: The total number of cycles was 189, of which 87 (46.03%) cycles were in the GnRH antagonist group and 102 (53.96%) in the PPOS group. The groups were similar with respect to age, anti-Müllerian hormone, body mass index as well as total gonadotropin consumption. There was no significant difference observed for the number of oocytes (P = 0.92), maturation rate (P = 0.07), fertilisation rate (P = 0.84), blastulation rate (P = 0.52), implantation rate (P = 0.36) and cumulative pregnancy rate (P = 0.63). The serum LH values before final oocyte maturation (suppressed LH) were similar (P = 0.09) in both the protocols.
CONCLUSION: IVF cycle outcomes with respect to oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation rates and cumulative pregnancy were comparable between GnRH antagonist and PPOS cycles. Furthermore, the extent of pituitary suppression, reflected by the serum LH levels before final oocyte maturation, was similar between the groups as observed in our analysis. However, these findings need to be validated by prospective studies or randomised trials with equal patient division.
AIM: The primary aim of this study was to compare IVF cycle outcomes in terms of oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation and cumulative pregnancy rate between gonadotropin-releasing hormone (GnRH) antagonist protocol and fixed PPOS protocol. The secondary aim was to compare the extent of pituitary suppression as reflected by serum LH before final oocyte maturation between both the protocols.
SETTINGS AND DESIGN: This was a retrospective observational cohort study.
MATERIALS AND METHODS: All ovarian stimulation cycles, either performed as GnRH-antagonist or as fixed PPOS, between 1st October 2023 and 15th July 2024, at a tertiary level IVF centre were included. Egg freezing cycles and donor egg cycles were excluded.
STATISTICAL ANALYSIS USED: Statistical tests applied were Student's t-test two-tailed for interval/ratio variables and the Chi-square test for nominal variables with a significance level of 0.05.
RESULTS: The total number of cycles was 189, of which 87 (46.03%) cycles were in the GnRH antagonist group and 102 (53.96%) in the PPOS group. The groups were similar with respect to age, anti-Müllerian hormone, body mass index as well as total gonadotropin consumption. There was no significant difference observed for the number of oocytes (P = 0.92), maturation rate (P = 0.07), fertilisation rate (P = 0.84), blastulation rate (P = 0.52), implantation rate (P = 0.36) and cumulative pregnancy rate (P = 0.63). The serum LH values before final oocyte maturation (suppressed LH) were similar (P = 0.09) in both the protocols.
CONCLUSION: IVF cycle outcomes with respect to oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation rates and cumulative pregnancy were comparable between GnRH antagonist and PPOS cycles. Furthermore, the extent of pituitary suppression, reflected by the serum LH levels before final oocyte maturation, was similar between the groups as observed in our analysis. However, these findings need to be validated by prospective studies or randomised trials with equal patient division.